


Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01, R21)

Epidemiology and Genomics Research Program
Behavioral Research Program
Health Care Delivery Research Program

Using WebEx and Webinar Logistics



- Submit questions at any time during the presentation. Type into the Q&A feature on the right of the interface and press “send”
 - Closed captioning is available by selecting the Media Viewer Panel on the right hand side of your screen
- To connect to the live audio, we recommend having the system call you. Enter your telephone number (include area code) and select “Call Me” OR dial in to the session at:
 - **Conference #:** 1-650-479-3207
 - **Access Code:** 730 963 232
- This webinar is being recorded

Webinar Presenters

- Wendy Nelson, PhD, MPH
Program Director, Basic Biobehavioral and Psychological Sciences Branch, NCI
- Kate Castro, RN, MS, AOCN
Program Director, Healthcare Delivery Research Program, NCI
- Kelly Filipski, PhD, MPH
Program Director, Clinical and Translational Epidemiology Branch, NCI

Agenda


- Background
- FOA Details
- Resources
- Questions

Questions about specific aims or grant application details will not be addressed

Background

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

NCI DCCPS Organizational Structure



The **Division of Cancer Control and Population Sciences (DCCPS)** aims to reduce cancer morbidity and mortality, as well as enhance the quality of life for cancer survivors.

cancercontrol.cancer.gov

Grant Mechanisms – R01 and R21

| NIH Research Project Grant (R01) PA-17-060 | NIH Exploratory/Developmental Grant (R21) PA-17-061 |
|---|--|
| <ul style="list-style-type: none">▪ Supports discrete, specified, circumscribed research projects▪ Most commonly used grant mechanism▪ No specific dollar limit<ul style="list-style-type: none">– Advance permission required for \geq\$500K direct costs in any year▪ 3-5 years of funding▪ Standard receipt dates | <ul style="list-style-type: none">▪ Supports exploratory/developmental research projects▪ May be used for pilot or feasibility studies▪ Preliminary data not required▪ Direct costs for the two-year project period may not exceed \$275K▪ 2 years of funding▪ Standard receipt dates |

For more information: grants.nih.gov/grants/funding/funding_program.htm#RSeries

FOA Details

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

Motivation

- Targeted oral anticancer (OAC) medications have transformed cancer care
- OAC medications offer many potential advantages over traditional IV chemotherapy
 - Superior effectiveness
 - Convenient home-based treatment
 - A sense of control over treatment
 - Avoid IV infusions, trips to infusion center
- Potential downsides of OAC medications
 - Complex treatment regimens, often in addition to other medication regimens
 - OAC medications require strict adherence to be effective
 - Patients/caregivers are responsible for symptom management
 - Financial burden
 - Difficulties acquiring OAC medication

Why do we need this funding opportunity announcement?

- Utilization
 - Little information is available on the adoption of newly approved targeted oral agents
 - Little information is available on off-label use of oral agents
 - Are targeted oral agents being prescribed appropriately?

- Adherence
 - Strict adherence is critical to achieving an optimal clinical outcome
 - Suboptimal adherence may lead to relapse, side-effects, unnecessary treatment changes, increased use of health care resources

- Health Care Delivery
 - Health care systems need to establish new roles, responsibilities, safety standards, patient education strategies for targeted oral therapies
 - Home-based treatment with targeted oral therapy requires new models of care coordination

Purpose

- Assess and describe the current state of oral anticancer medication utilization, adherence, and delivery
- Identify the structural, systemic, and psychosocial barriers to adherence
- Develop models and strategies to improve safe and effective delivery of oral anticancer agents so that clinical outcomes are optimized

Considerations

- Applicants should focus on at least one of the following
 - Specific type of cancer
 - Class of drugs
 - Patients subject to disparities

- Studies may be observational/descriptive or include interventions; observational studies should emphasize modifiable factors for future interventions

- Studies may focus on utilization, adherence, or health care delivery issues related to oral anticancer agents (no need to study everything)

- Consult your Program Director if you have questions

Research Priorities

- Cross-disciplinary collaborations (e.g., pharmacists, research nurses, social workers, financial navigators)
- Studies focused on newer molecularly targeted therapies
- Primary data collection is encouraged

Utilization Challenges

- Understand how targeted therapies are being prescribed and used
 - Disparities in access
 - Off-label use

- Potential research questions:
 - What are the patient and provider characteristics associated with prescribing and use of molecularly targeted agents?
 - Are there sociodemographic or health-related factors (e.g., comorbidities) that affect utilization?
 - What are current trends in utilization of newly approved targeted oral therapies?

Adherence Challenges

- Understand how cognitive, affective, and motivational processes influence adherence behavior
 - Beliefs about the safety and effectiveness of a “pill”
 - Depression, anxiety

- Potential research questions:
 - How do patients perceive the risks associated with oral therapy, and how do these risk perceptions influence adherence?
 - Are there major differences in patterns of adherence depending on the duration or complexity of the treatment regimen?
 - How do financial considerations (e.g., out-of-pocket costs) influence adherence?

Health Care Delivery Challenges

- Understand how health care delivery systems are adapting to meet safety standards and the educational needs of patients and caregivers
 - Symptom management
 - Coordination of care

- Potential research questions:
 - What system, health care team, provider, and patient-level factors are associated with the safe administration of oral agents?
 - How does reimbursement affect symptom management and monitoring?
 - What features of health care delivery systems lead to improved safety and adherence?

Resources

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

Read the FOAs Carefully

- PA-17-060 (R01); PA-17-061 (R21)
- Upcoming R01 application due dates: **June 5, 2017; October 5, 2017**
- Upcoming R21 application due dates: **June 16, 2017; October 16, 2017**
- Start the process early! Allow time for registration in Grants.gov and NIH eRA Commons
- Verify successful submission by checking the eRA Commons

Program Contacts

- Wendy Nelson, PhD
Nelsonw@mail.nih.gov
240-276-6971
Adherence
- Kate Castro, RN, MS, AOCN
Kathleen.Castro@nih.gov
240-276-6834
Health Care Delivery
- Kelly Filipski, PhD
Kelly.Filipski@nih.gov
240-276-6841
Utilization

Questions

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

Next Steps

- Email additional questions to ncidccpsbrpadvances@mail.nih.gov.
- Today's webinar and list of Q&As (both leading up to and following the webinar) will be posted online:
 - cancercontrol.cancer.gov/brpwebinars

U.S. Department of Health & Human Services
National Institutes of Health / National Cancer Institute

cancercontrol.cancer.gov

1-800-4-CANCER